A
A

Ashmore

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Turkish lira slips as inflation jumps above interest rate

* Turkish inflation at 19.25%, more than estimates of 18.7% * Turkey cenbank will likely hold rate this month - analyst * Chinese, Russian service PMIs fall, India's rises * EM shares inch toward 6-week highs; eyes on US payrolls data By Susan Mathew Sept 3 (Reuters) - Turkey's lira fell up to 0.8% on Friday after inflation jumped more than expecte
A
E
U
U
U
P

Energy, pharma stocks drag FTSE 100 lower; dismal service activity data

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * Discoverie Group rises after upsizing equity raise * Sanne Group falls after Cinven steps back from bidding war * UK economic recovery slows down as supply chain issues weigh * FTSE 100 down 0.4%, FTSE 250 off 0.1% (Updates to close) By De
A
U

UK Stocks-Factors to watch on Sept 3

Sept 3 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening 1 point lower on Friday, according to financial bookmakers. * JOBS: Employers in Britain are still hunting for more recruits than they were just before the pandemic, according to a survey which added to signs of a tight labour market following the COVID-19 lockdowns and Brexit. * SHE
A
B
B
U

Ashmore Group returns hit by China debt exposure, says Credit Suisse

By Tom Arnold and Joice Alves LONDON, Aug 6 (Reuters) - Ashmore Group's ASHM.L exposure to Chinese debt is dragging down its returns, Credit Suisse said in a note on Friday as it lowered its price target on the emerging market specialist, sending its share price down almost 4% in early trade. Worries about debt woes at developer China Evergrande Gr
A

UK Stocks-Factors to watch on July 14

July 14 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening 5 points lower at 7,120 on Wednesday, according to financial bookmakers, with futures FFIc1 down 0.2%. * ASTRAZENECA: Britain's competition regulator said it has cleared AstraZeneca's AZN.L $39 billion buyout of U.S.-based Alexion ALXN.O after it decided not to initiate a broader pr
A
A
B
T
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.